scholarly journals Ex Vivo Lung Perfusion with K(ATP) Channel Modulators Antagonize Ischemia Reperfusion Injury

Cells ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 2296
Author(s):  
Stephan Arni ◽  
Tatsuo Maeyashiki ◽  
Tsogyal Latshang ◽  
Isabelle Opitz ◽  
Ilhan Inci
Keyword(s):  
Reperfusion Injury ◽  
Ischemia Reperfusion Injury ◽  
Ex Vivo ◽  
Ischemia Reperfusion ◽  
Lung Perfusion ◽  
Metabolic Parameters ◽  
Physiological Data ◽  
Control Group ◽  
Ex Vivo Lung Perfusion ◽  
Ischemic Time

Ex vivo lung perfusion (EVLP) has been implemented to increase the number of donor lungs available for transplantation. The use of K(ATP) channel modulators during EVLP experiments may protect against lung ischemia-reperfusion injury and may inhibit the formation of reactive oxygen species. In a rat model of donation after circulatory death with 2 h warm ischemic time, we evaluated rat lungs for a 4-hour time in EVLP containing either mitochondrial-specific or plasma membrane and/or sarcolemmal-specific forms of K(ATP) channel modulators. Lung physiological data were recorded, and metabolic parameters were assessed. When compared to the control group, in the EVLP performed with diazoxide or 5-hydroxydecanoic acid (5-HD) we recorded significantly lower pulmonary vascular resistance and only in the diazoxide group recorded significant lung weight loss. In the perfusate of the 5-HD group, interleukin-1β and interleukin-1α were significantly lower when compared to the control group. Perfusate levels of calcium ions were significantly higher in both 5-HD and cromakalim groups, whereas the levels of calcium, potassium, chlorine and lactate were reduced in the diazoxide group, although not significantly when compared to the control. The use of a diazoxide mitochondrial-specific K(ATP) channel opener during EVLP improved lung physiological and metabolic parameters and reduced edema.

scholarly journals Plasmin administration during ex vivo lung perfusion ameliorates lung ischemia–reperfusion injury

2014 ◽  
Vol 33 (10) ◽  
pp. 1093-1099 ◽  
Author(s):  
Hideki Motoyama ◽  
Fengshi Chen ◽  
Kyoko Hijiya ◽  
Takeshi Kondo ◽  
Akihiro Ohsumi ◽  
...  
Keyword(s):  
Reperfusion Injury ◽  
Ischemia Reperfusion Injury ◽  
Ex Vivo ◽  
Ischemia Reperfusion ◽  
Lung Perfusion ◽  
Ex Vivo Lung Perfusion

scholarly journals A porcine ex vivo lung perfusion model with maximal argon exposure to attenuate ischemia-reperfusion injury

2017 ◽  
Vol 7 (1) ◽  
pp. 28 ◽  
Author(s):  
ArneP Neyrinck ◽  
An Martens ◽  
Sofie Ordies ◽  
BartM Vanaudenaerde ◽  
StijnE Verleden ◽  
...  
Keyword(s):  
Reperfusion Injury ◽  
Ischemia Reperfusion Injury ◽  
Ex Vivo ◽  
Ischemia Reperfusion ◽  
Lung Perfusion ◽  
Ex Vivo Lung Perfusion ◽  
Perfusion Model

scholarly journals Ischemia–Reperfusion Injury in Lung Transplantation

Cells ◽  
2021 ◽  
Vol 10 (6) ◽  
pp. 1333
Author(s):  
Toyofumi Fengshi Chen-Yoshikawa
Keyword(s):  
Lung Transplantation ◽  
Reperfusion Injury ◽  
Ischemia Reperfusion Injury ◽  
Ex Vivo ◽  
Ischemia Reperfusion ◽  
Severe Form ◽  
Inhalation Therapy ◽  
Ex Vivo Lung Perfusion ◽  
Pulmonary Endothelium ◽  
End Stage

Lung transplantation has been established worldwide as the last treatment for end-stage respiratory failure. However, ischemia–reperfusion injury (IRI) inevitably occurs after lung transplantation. The most severe form of IRI leads to primary graft failure, which is an important cause of morbidity and mortality after lung transplantation. IRI may also induce rejection, which is the main cause of mortality in recipients. Despite advances in donor management and graft preservation, most donor grafts are still unsuitable for transplantation. Although the pulmonary endothelium is the primary target site of IRI, the pathophysiology of lung IRI remains incompletely understood. It is essential to understand the mechanism of pulmonary IRI to improve the outcomes of lung transplantation. Therefore, we reviewed the state-of-the-art in the management of pulmonary IRI after lung transplantation. Recently, the ex vivo lung perfusion (EVLP) system has been clinically introduced worldwide. Various promising therapeutic strategies for the protection of the endothelium against IRI, including EVLP, inhalation therapy with therapeutic gases and substances, fibrinolytic treatment, and mesenchymal stromal cell therapy, are awaiting clinical application. We herein review the latest advances in the field of pulmonary IRI in lung transplantation.

scholarly journals A Preclinical Systematic Review of Curcumin for Protecting the Kidney with Ischemia Reperfusion Injury

2020 ◽  
Vol 2020 ◽  
pp. 1-17
Author(s):  
Zi-Hao Wang ◽  
Li-Hui Deng ◽  
Chang-Wei Chi ◽  
Hong Wang ◽  
Yue-Yue Huang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Animal Models ◽  
Serum Creatinine ◽  
Reperfusion Injury ◽  
Ischemia Reperfusion Injury ◽  
Biological Activities ◽  
Ischemia Reperfusion ◽  
Risk Of Bias ◽  
Control Group ◽  
Ischemic Time

Renal ischemia-reperfusion injury (RIRI) refers to a phenomenon associated with dysfunction of the kidney and tissue damage. Unfortunately, no specific drugs have been found that effectively prevent and treat RIRI. Curcumin (Cur), a polyphenol extracted from turmeric, possesses a variety of biological activities involving antioxidation, inhibition of apoptosis, inhibition of inflammation, and reduction of lipid peroxidation. Eight frequently used databases were searched using prespecified search strategies. The CAMARADES 10-item quality checklist was used to evaluate the risk of bias of included studies, and the RevMan 5.3 software was used to analyze the data. The risk of bias score of included studies ranged from 3 to 6 with an average score of 5.22. Compared with the control group, Cur significantly alleviated renal pathology, reduced blood urea nitrogen and serum creatinine levels, and improved inflammatory indexes, oxidant, and apoptosis in RIRI animal models. Despite the heterogeneity of the response to Cur in terms of serum creatinine, BUN, TNF-alpha, and SOD, its effectiveness for improving the injury of RIRI was remarkable. In the mouse model subgroup of serum creatinine, the effect size of the method of unilateral renal artery ligation with contralateral nephrectomy and shorter ischemic time showed a greater effect than that of the control group. No difference was seen in the methods of model establishment, mode administration, or medication times. The preclinical systematic review provided preliminary evidence that Cur partially improved RIRI in animal models, probably via anti-inflammatory, antioxidant, antiapoptosis, and antifibrosis activities and via improving microperfusion. ARRIVE guidelines are recommended; blinding and sample size calculation should be focused on in future studies. These data suggest that Cur is a potential renoprotective candidate for further clinical trials of RIRI.

Sign in / Sign up

Export Citation Format

Share Document